Related Experiment Video
Updated: Feb 8, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions
1Center for Clinical Trials, Städtisches Klinikum Dessau, Dessau, Germany.
Abstract:
Antineoplastic agents directly targeting tumor cells have represented the major strategy of systemic anticancer therapy for many years. Nevertheless, overcoming resistance mechanisms remains a great challenge because treatment options are limited in many cases. From this point of view, immunotherapeutic approaches seem promising in a broad spectrum of solid tumors. These include in particular the currently available inhibitors directed against immune checkpoints leading to a significant T-cell activation. To date, the programmed death receptor 1 (PD-1) and its ligand are the most prominent targets in this context. However, the role of checkpoint inhibitors in the treatment of breast cancer is still being debated, and the main focus is on triple-negative breast cancer patients as a target population in many ongoing trials. Moreover, the potential superiority of combinations with other anticancer drugs such as cytotoxics and targeted agents will be discussed.
Insights
Immunotherapy, particularly targeting immune checkpoints like programmed death receptor 1 (PD-1), shows promise for solid tumors, including breast cancer. Research is exploring its effectiveness, especially in triple-negative breast cancer and combination therapies.
Area of Science:
- Oncology
- Immunology
- Cancer Therapy
Background:
- Systemic anticancer therapies have long focused on direct tumor cell targeting.
- Overcoming drug resistance and limited treatment options remain significant challenges in cancer therapy.
- Immunotherapeutic approaches offer a promising alternative for a wide range of solid tumors.
Purpose of the Study:
- To review the role of immune checkpoint inhibitors in cancer treatment.
- To discuss the specific application and ongoing research of PD-1/PD-L1 inhibitors in breast cancer, particularly triple-negative breast cancer.
- To explore the potential benefits of combining immunotherapy with other anticancer agents.
Main Methods:
- Literature review and analysis of current research on immune checkpoint inhibitors.
- Focus on programmed death receptor 1 (PD-1) and its ligand (PD-L1) as therapeutic targets.
- Discussion of clinical trials and treatment strategies for breast cancer.
Main Results:
- Immune checkpoint inhibitors, especially PD-1 inhibitors, have demonstrated significant T-cell activation.
- The efficacy of these inhibitors in breast cancer treatment is under investigation, with a focus on triple-negative subtypes.
- Combinations of immunotherapy with cytotoxic and targeted agents are being explored for enhanced efficacy.
Conclusions:
- Immunotherapy, particularly PD-1 pathway inhibition, represents a significant advancement in cancer treatment.
- Further research is needed to establish the role of checkpoint inhibitors in breast cancer and optimize combination strategies.
- Triple-negative breast cancer is a key focus for current and future immunotherapy trials.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Marcia's Theory of Identity Status
Electrical Current
Directing Effect of Substituents: meta-Directing Groups

